Merck KGaA (OTCMKTS:MKGAF) Sets New 1-Year High at $117.14

Merck KGaA (OTCMKTS:MKGAF) shares reached a new 52-week high during trading on Monday . The stock traded as high as $117.14 and last traded at $117.14, with a volume of 12 shares. The stock had previously closed at $116.90.

Separately, ValuEngine downgraded Merck KGaA from a “sell” rating to a “strong sell” rating in a report on Saturday, October 5th.

The firm has a fifty day simple moving average of $111.75 and a 200 day simple moving average of $106.76. The company has a market capitalization of $14.99 billion, a PE ratio of 20.45 and a beta of 0.72. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.68 and a current ratio of 0.94.


MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: Insider Trading – What You Need to Know

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with's FREE daily email newsletter.